Results 271 to 280 of about 214,361 (343)

Management of peri‐implant soft tissue dehiscence with combined prosthetic‐surgical approach: A case report

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background This case report presents the management of an esthetic complication of a peri‐implant soft tissue dehiscence (PSTD) through a combined prosthetic‐surgical approach. Methods and Results A 53‐year‐old healthy Hispanic male presented to our practice for the treatment of an implant esthetic complication. A diagnosis of PSTD class III C
Omran Bishbish Zeino, Yoon Jeong Kim
wiley   +1 more source

Corrigendum to ‘Society of Cardiovascular Anesthesiologists (SCA) Clinical Practice Improvement (CPI) Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients’ [Journal of Cardiothoracic and Vascular Anesthesia 33 (2019) 2887-2899]

open access: green, 2019
Jacob Raphael   +28 more
openalex   +2 more sources

Human Protein Z as the Second Known Heme‐Binding Protein from the Endogenous Blood Coagulation Inhibitor System

open access: yesChemBioChem, EarlyView.
Protein Z is a vitamin K‐dependent anticoagulant with elusive molecular functions. Herein, it is shown that heme binds to protein Z and induces conformational changes. One histidine‐based heme‐binding motif is identified. High heme‐binding affinity and functional effects are demonstrated on protein level. These findings shed new light on the structural
Paula Lindemann, Marie‐T. Hopp
wiley   +1 more source

Contemporary and Emerging Therapies in the Management of Refractory Angina: A Clinical Review

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization.
Alex Angers‐Goulet   +4 more
wiley   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou   +12 more
wiley   +1 more source

Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Real‐world edoxaban concentrations in older patients receiving reduced‐dose regimens. Low trough concentrations (< 12 ng/mL) were associated with an increased risk of thromboembolism. Among patients meeting the ELDERCARE‐AF criteria, low drug levels were more frequent with the 15 mg regimen than with the 30 mg regimen.
Sung‐Chun Tang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy